Intended for US Healthcare Professionals Only
KEDRAB® (Rabies Immune Globulin [Human]) is a biologic prepared by chromatographic fractionation from a pool of plasma collected from selected US adult human donors who have been immunized with rabies vaccine and have developed high titers of anti-rabies antibody.1
KEDRAB is derived from human plasma; therefore, the potential exists that KEDRAB administration may transmit infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.2
Get detailed information about the rabies virus, current post-exposure prophylaxis guidelines, and the efficacy and safety of KEDRAB for rabies exposure.
If you are interested in receiving the most current information about KEDRAB, proper PEP, and educational rabies resources, enroll now.
References: 1. Data on file. Kamada Ltd. 2. KEDRAB [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.; 2021. 3. FDA acceptance of BLA submission for human rabies immunoglobulin [press release]. Fort Lee, NJ/Ness Ziona, Israel: November 8, 2016.